NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Cronos Group Inc. (CRON) Stock Analysis

Cronos Group Inc. (CRON) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CRON

$3.39

+$0.11 (+3.35%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRON with… →

CRON Key Statistics

As of Oct 21, 2026
Trading
Open
$3.29
Previous Close
$3.28
Day's Range
3.27–3.44
52-Week Range
2.28–3.61
Volume
1.13M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.20
Valuation
Market Cap
$1.25B
P/E Ratio
17.84
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.97
EPS (ttm)Profit attributable to each share over the last twelve months.
0.19
Financials (FY)
Revenue (FY)
$146.59M+24.63%
Net Income (FY)
−$9.45M−123.00%
Profit marginThe share of revenue left as profit after all costs and taxes.
39.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
368.41M
1-Year Return
+35.60%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.15M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CRON closed at $3.39, +35.60% over 1 year.

Cronos Group Inc. (CRON) has a market capitalization of $1.25B.

In fiscal 2025, CRON reported revenue of $146.59M.

CRON Stock Return by Calendar Year

Cronos Group Inc. (CRON) return since Feb 2018: what $10,000 became

1 year
$10,000 $13,560
+35.60%
5 years
$10,000 $5,697
−43.03%
Since Feb 2018
$10,000 $4,449
−55.51%

If you had invested $10,000 in Cronos Group Inc. (CRON) at the close on February 27, 2018, the earliest close on record here, it would have been worth $4,449 at the close on October 21, 2026: −55.51% in total, −8.94% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+28.90%
2025+30.20%
2024−3.35%
2023−17.72%
2022−35.20%
2021−43.52%
2020−9.52%
2019−26.18%
2018 (partial year)+36.35%

As of October 21, 2026.

CRON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$146.59M−$9.45M−6.4%
2024$117.62M$41.08M34.9%
2023$87.24M−$73.96M−84.8%
2022$86.75M−$168.73M−194.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$146.59M$62.76M−$19.50M−$9.45M−6.4%
2024$117.62M$25.20M−$59.55M$41.08M34.9%
2023$87.24M$11.91M−$79.91M−$73.96M−84.8%
2022$86.75M$15.44M−$104.39M−$168.73M−194.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRON Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricCRONDrug Manufacturers - Specialty & Generic medianvs median
P/E17.8420.3112% below
P/S ratio6.972.103.3x the median
Profit margin39.08%−8.14%47.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cronos Group Inc. (CRON) carries a market capitalisation of $1.25B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 610 employees.

Over the past 52 weeks the price has ranged from $2.28 to $3.61. CRON last closed at $3.39 on October 21, 2026. That is +$0.11 (+3.35%) against the previous close. The latest close sits 48.68% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $146.59M. Against the prior fiscal year total of $117.62M, that is a change of +24.63%. The same year closed with a net loss of $9.45M. The reported profit margin is 39.08%. That is 47.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 0.19.

Across the 4 fiscal years on file, revenue moves from $86.75M in 2022 to $146.59M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 17.84. That is 12.18% below the Drug Manufacturers - Specialty & Generic median of 20.31. Measured against sales, the shares trade at 6.97 times revenue. On price-to-sales that is 3.3 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the total return is +35.60%. Across 5 years the annualized return works out at −10.64%. Beta against the wider market is reported at 1.2. Daily returns over the trailing 8 years annualize to a volatility of 61.53%.

Growth & Income

No dividend is on file for CRON.

Across the complete calendar years on file, 2025 returned +30.20% and 2021 returned −43.52%. Of the 7 complete calendar years on file, 1 finished higher. So far in 2026 the total return is +28.90%.

Peer Comparison

Cronos Group Inc. (CRON) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cronos Group Inc. CRON $1.25B 17.8
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Cronos Group Inc. trades at a P/E of 17.8.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cronos Group Inc.

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Visit website →